Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:GILD News 22 December 2025 - 28 January 2026

Gilead stock dips as Medicare targets Biktarvy for 2028 price talks — and Trodelvy gets a guideline lift

Gilead stock dips as Medicare targets Biktarvy for 2028 price talks — and Trodelvy gets a guideline lift

Gilead Sciences shares fell 1.3% to $139.19 Wednesday afternoon after Medicare named its HIV drug Biktarvy for 2026 price negotiations, with caps set to start in 2028. The company also reported its cancer drug Trodelvy was upgraded to “category 1” in new NCCN breast cancer guidelines. Investors await Gilead’s earnings on Feb. 10.
28 January 2026
··
Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Gilead Sciences shares rose 2.3% to $140.97 Tuesday, hitting a 52-week high after Medicare named its HIV drug Biktarvy for price negotiations starting in 2028. Trading volume topped 10.5 million shares. CEO Daniel O’Day sold 115,640 shares last week under a pre-set plan. Gilead will report fourth-quarter and full-year results after markets close on Feb. 10.
28 January 2026
···
Gilead stock hits fresh 52-week high as Wall Street lifts targets into earnings

Gilead stock hits fresh 52-week high as Wall Street lifts targets into earnings

Gilead Sciences shares rose 1.8% to $140.24 Tuesday afternoon, hitting a 12-month high of $141.69 earlier in the session. Citi, Truist, and BMO raised price targets following upbeat analyst notes and strong momentum for the company’s HIV prevention drug Yeztugo. Investors await early February results and Gilead’s earnings, expected around Feb. 10.
27 January 2026
·····
Gilead (GILD) stock hits fresh 52-week high as new analyst targets and CEO sale filing land

Gilead (GILD) stock hits fresh 52-week high as new analyst targets and CEO sale filing land

Gilead Sciences shares closed at a 52-week high of $137.78 on Monday, up 1.36% for a fourth straight gain. CEO Daniel O’Day sold $15.6 million in stock under a pre-set plan, according to an SEC filing. BMO and UBS raised their price targets, citing momentum in HIV drugs and new coverage for Yeztugo. Trading volume exceeded normal levels as the stock outperformed major pharma peers.
27 January 2026
····
Gilead stock ticks up after BMO lifts target to $150, flags Yeztugo coverage gains

Gilead stock ticks up after BMO lifts target to $150, flags Yeztugo coverage gains

Gilead Sciences shares rose 0.9% to $137.21 midday Monday after BMO Capital Markets raised its price target to $150, citing expanded insurance coverage for Yeztugo, Gilead’s new HIV prevention shot. CVS confirmed coverage starting Jan. 1, pushing overall insurer coverage above 80%. Gilead says it has already met its 2025 Yeztugo sales target of $150 million. Investors await Gilead’s earnings report, expected Feb. 10.
26 January 2026
·····
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

Gilead Sciences shares rose 3.65% to $135.93 after Phase 3 trial results showed Trodelvy plus Keytruda cut the risk of breast cancer progression or death by 35% versus Keytruda and chemotherapy. The company has submitted regulatory filings in the U.S. and Europe. CEO Daniel O’Day plans to sell up to $15.6 million in shares. Investors await Gilead’s earnings report on Feb. 10.
24 January 2026
····
Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead Sciences shares slipped 0.2% to $124.68 Tuesday, outperforming a broader market drop. Bernstein reiterated its Outperform rating and $135 target, citing Yeztugo as a key 2026 driver. Florida announced steep cuts to its AIDS Drug Assistance Program, drawing criticism from advocates and raising concerns over HIV drug access.
20 January 2026
···
Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit

Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit

NEW YORK, December 29, 2025, 22:17 ET — Market closed Gilead Sciences (GILD.O) shares were last up 0.15% at $124.91 on Monday, as investors weighed an analyst note that argued new Medicaid drug-pricing rules would have a limited financial impact on the company’s HIV franchise. Investing.com The call matters now because drugmakers and investors are still parsing a Trump administration pricing push that targets Medicaid and aims to bring U.S. medicine prices closer to those in other wealthy countries. Reuters For Gilead, the focus has been on whether “most-favored-nation” pricing — a policy that effectively ties prices to lower international
30 December 2025
·····
Gilead Sciences Stock (GILD) After Hours: What to Know Before the Market Opens on Dec. 24, 2025

Gilead Sciences Stock (GILD) After Hours: What to Know Before the Market Opens on Dec. 24, 2025

Gilead Sciences, Inc. (NASDAQ: GILD) ended the Dec. 23, 2025 session modestly higher and was little changed after the closing bell—a calm tape that masks a busy fundamental backdrop heading into a holiday-shortened Christmas Eve trading day. As investors look toward Wednesday’s open (Dec. 24, 2025), the “what matters” list for GILD is less about tonight’s after-hours tick and more about the headlines that could shape sentiment into year-end: Gilead’s move to expand its antiviral pipeline with a new herpes program, the company’s upcoming J.P. Morgan Healthcare Conference appearance, and the still-fresh U.S. drug-pricing/tariff-relief agreements that are reshaping how big
24 December 2025
····
Gilead Sciences (GILD) Stock After Hours on Dec. 22, 2025: What’s Moving Shares and What to Watch Before Tuesday’s Open

Gilead Sciences (GILD) Stock After Hours on Dec. 22, 2025: What’s Moving Shares and What to Watch Before Tuesday’s Open

Gilead Sciences, Inc. (NASDAQ: GILD) ended the regular session on Monday, December 22, 2025 essentially flat, and the stock showed only a modest change in post-market trading—yet the news flow behind the scenes was anything but quiet. After the closing bell, investors were digesting a fresh antiviral pipeline update tied to a new genital herpes program, plus a newly confirmed appearance at January’s heavyweight healthcare investor conference—both of which can shape sentiment as markets reopen on Tuesday, December 23, 2025. StockAnalysis+2Gilead+2 GILD after-hours check: where the stock stands tonight Here’s the key price action from Monday’s session and the after-hours
23 December 2025
····
Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences, Inc. (NASDAQ: GILD) opened the holiday-shortened week with a mix of pipeline expansion and policy-driven uncertainty—two themes that can quickly move large-cap biopharma stocks even when overall market volume is lighter than usual. On Monday, December 22, 2025, Gilead announced it has exercised its option to license Assembly Biosciences’ investigational herpes simplex virus (HSV) programs—a move that strengthens Gilead’s long-term antiviral pipeline beyond HIV. The development lands just days after Gilead joined other major drugmakers in a Trump administration “most-favored-nation” drug-pricing agreement tied to tariff relief and direct-to-consumer drug access via TrumpRx.gov. Gilead+2Gilead+2 As of the latest available
22 December 2025
·····
Gilead Sciences (GILD) Stock: What to Know Before the Market Opens on December 22, 2025

Gilead Sciences (GILD) Stock: What to Know Before the Market Opens on December 22, 2025

Ahead of the U.S. market open on Monday, December 22, 2025 (the next trading session after Friday’s close), Gilead Sciences, Inc. (NASDAQ: GILD) is in focus for two reasons that matter to both short-term traders and long-term investors: a new U.S. government drug-pricing agreement that could reshape near-term sentiment across big pharma, and fresh late-stage HIV pipeline success that reinforces Gilead’s core franchise heading into 2026. Gilead+1 Below is a market-ready briefing—current catalysts, what analysts are watching, key numbers, and the biggest risks—written for readers looking to understand what could move GILD stock as the bell approaches. GILD stock snapshot
22 December 2025
····
1 2

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Go toTop